Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Amarin Corporation announced that Australia's Therapeutic Goods Administration (TGA) has approved VAZKEPA (icosapent ethyl) for reducing the risk of cardiovascular (CV) events in adult statin-treated patients with high CV risk and elevated triglycerides. This marks the fifth regulatory approval for the VAZKEPA franchise in key international markets in 2022. The company will initiate the reimbursement process to support commercialization in Australia, backed by patents providing market exclusivity into the early 2030s.
Amarin Corporation (NASDAQ:AMRN) announced that CEO Karim Mikhail will participate in the Jefferies London Healthcare Conference from November 15-17, 2022. Mikhail's presentation is scheduled for November 16, 2022, at 9:40 a.m. ET (2:40 p.m. GMT+1).
This event will be webcast live, with an archived version available on Amarin's Investor Relations website. The company focuses on advancing cardiovascular disease management through scientific research and clinical trials.
Amarin Corporation presents key findings from the RESPECT-EPA study at the AHA 2022 Scientific Sessions, highlighting the cardiovascular risk reduction benefits of eicosapentaenoic acid (EPA) for patients with coronary artery disease (CAD). The study demonstrated a 21.5% reduction in cardiovascular risk (p=0.054) and a 26.6% reduction in a secondary endpoint (p=0.03). In contrast, the PROMINENT study reported no cardiovascular benefits from the fibrate class for high-risk patients. The results reinforce the therapeutic value of VASCEPA/VAZKEPA in managing cardiovascular risk alongside statin therapy.
Amarin Corporation (NASDAQ:AMRN) announced Q3 2022 financial results, reporting a net revenue of $89.9 million, down 37% from Q3 2021, largely due to increasing generic competition affecting VASCEPA sales. The company secured positive reimbursement assessments in several European markets, including Finland and the Netherlands, and launched VAZKEPA in the UK. Efforts to stabilize US revenues continued, achieving a cash-positive quarter excluding restructuring charges. Amarin's cost-saving measures are projected to yield $100 million by mid-2023, extending its cash runway amid ongoing market access negotiations.
Amarin Corporation plc (NASDAQ:AMRN) has announced the retirement of Lars Ekman and Patrick O’Sullivan from its Board of Directors effective year-end, following a significant refreshment program. Adam Berger and Geraldine Murphy are appointed as new independent directors, contributing extensive international experience in healthcare and finance. With 75% of the board refreshed over the past year, the company aims to enhance its expertise to support global expansion and strategic objectives. This leadership change is designed to align with Amarin's mission to advance cardiovascular disease management.
Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on October 27, 2022, at 8:00 a.m. ET to discuss its third quarter 2022 financial results. The call follows the pre-market release of the financial results. Interested parties can access the live call through the investor relations section of Amarin's website or via dial-in options provided for both U.S. and international participants. A replay of the call will also be available after the event through the website.
Amarin Corporation plc (NASDAQ:AMRN) announced significant changes in its Board of Directors, emphasizing an active board refreshment process. The board supports a new strategic direction aimed at expanding its business in Europe and enhancing U.S. operations. In 2022, three independent directors with extensive biotech and pharmaceutical experience were appointed. The board is in the final stages of appointing new directors and remains committed to constructive engagement with shareholders, including Sarissa Capital Management.
Sarissa Capital Management has expressed concerns over Amarin Corporation's management, urging immediate representation on the board to restore shareholder value. Sarissa highlighted that shareholders have lost over $850 million this year, with a 64% stock decline. Following the annual meeting, stock prices dropped another 38%, equating to a loss of $280 million for shareholders. Sarissa warns that continued mismanagement may lead to cash shortages and the need for dilutive capital raises. They plan to solicit votes for new board members at a special meeting.
Amarin Corporation plc (NASDAQ:AMRN) announced that Karim Mikhail, the president and CEO, will speak at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 9:00 a.m. ET. This event will take place in New York City from September 12-14, 2022. A live webcast of the presentation will be available here.
Amarin focuses on cardiovascular disease management and aims to advance treatments through scientific understanding.
Amarin Corporation (NASDAQ:AMRN) announced significant findings from its REDUCE-IT study, presented at the ESC Congress 2022. The data reveals that VASCEPA/VAZKEPA (icosapent ethyl) reduced first cardiovascular events by 23% in current smokers and 29% in former smokers compared to placebo. The incidence of cardiovascular events in current and former smokers using IPE was similar to that of never smokers. These results highlight the potential of IPE in mitigating cardiovascular risks associated with smoking history.